PROGEN acquires EuroProxima’s research antibodies
PROGEN Biotechnik GmbH expands portfolio in the cell biology market
PROGEN Biotechnik GmbH has recently acquired the research antibody line of the Dutch company EuroProxima B.V., a global provider of immunobiological test systems. The deal encompasses about 190 products that supplement PROGEN’s portfolio of proprietary immunochemicals.

Specific immunofluorescent labeling of skin cells with PROGEN’s keratin antibody GP-K1 (green staining)
PROGEN Biotechnik GmbH
The purchase is part of PROGEN’s expansion in the cell biology research antibody market. Dr. Sven Kuhlendahl, General Manager of PROGEN: “It is a pleasure to announce the integration of EuroProxima’s high-class antibodies into our own portfolio of over 500 antibodies. The addition of keratin and hormone antibodies in particular complement our product range substantially. We are now in an excellent position to serve research laboratories worldwide with a broad variety of immunochemical tools.”
PROGEN reaches out to potential partners in its endeavor to further expand its research reagents business. This includes monoclonal and recombinant antibodies as well as immunochemical tests supporting the validity of cell biology experiments.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous